Epigenetic modification, including histone modification, precisely controls target gene expression. The posttranscriptional regulation of the innate signaling-triggered production of inflammatory cytokines and type I interferons has been fully elucidated, whereas the roles of histone modification alteration and epigenetic modifiers in regulating inflammatory responses need to be further explored. Di/tri-methylation modifications of histone 3 lysine 79 (H3K79me2/3) have been shown to be associated with gene transcriptional activation. Disruptor of telomeric silencing-1-like (Dot1l) is the only known exclusive H3K79 methyltransferase and regulates the proliferation and differentiation of tumor cells. However, the roles of Dot1l and Dot1l-mediated H3K79 methylation in innate immunity and inflammatory responses remain unclear. Here, we found that H3K79me2/3 modification levels at the Il6 and Ifnb1 promoters, as well as H3K79me2 modification at the Tnfα promoter, were increased in macrophages activated by Toll-like receptor (TLR) ligands or virus infection. The innate signals upregulated Dot1l expression in macrophages and THP1 cells. Dot1l silencing or a Dot1l inhibitor preferentially suppressed the production of IL-6 and interferon (IFN)-β but not of TNFα in macrophages and THP1 cells triggered by TLR ligands or virus infection. Dot1l was recruited to the proximal promoter of the Il6 and Ifnb1 but not Tnfα gene and then mediated H3K79me2/3 modification at the Il6 and Ifnb1 promoters, consequently facilitating the transcription and expression of Il6 and Ifnb1. Thus, Dot1l-mediated selective H3K79me2/3 modifications at the Il6 and Ifnb1 promoters are required for the full activation of innate immune responses. This finding adds new insights into the epigenetic regulation of inflammatory responses and pathogenesis of autoimmune diseases.
INTRODUCTION
Pattern-recognition receptors (PRRs) are essential for innate immune cells to initiate the innate immunity and inflammatory response. 1 Upon sensing foreign pathogens or endogenous ligands, PRRs activate downstream signaling pathways, thus inducing the production of inflammatory cytokines and type I interferon (IFN). 2 Insufficient activation of PRR signaling leads to uncontrolled or persistent pathogen infection, whereas overproduction of inflammatory cytokines or type I IFN is involved in various inflammatory or autoimmune diseases. 3, 4 Thus, the precise balance between positive and negative regulation of PRR signaling is necessary for pathogen clearance and inflammatory disease avoidance. 5, 6 The regulation modes of cytoplasmic PRR signaling are commonly associated with posttranslational protein modifications of PRRs or downstream signaling molecules, including protein phosphorylation, ubiquitination, and acetylation, which have been widely investigated. 7, 8 However, the regulation mechanism for nuclear processes of innate inflammatory responses is still elusive.
The activation of innate immune responses can lead to nuclear reprogramming and epigenetic modification change, and these epigenetic modifications are crucial for transcriptional regulation of innate immune genes. [9] [10] [11] Different epigenetic modifications of histones, DNAs, and RNAs, together with their associated proteins and epigenetic regulators play diverse key roles in gene transcription and expression. 12, 13 Histone methylation is one type of the most important epigenetic modifications associated with both transcription activation and repression owing to different modification locations and statuses (mono-, di-, or tri-methylation). 12 The tri-methylation of histone 3 at lysine 4 (H3K4me3) and some other histone modification modes (H3K36me3 and H4K20me1) are defined as gene activation markers, whereas H3K27me3 and H4K20me3 are associated with inhibition of gene transcription. 14 The lysine-specific methyltransferases (KMTs) and demethylases (KDMs) cooperatively mediate the dynamic level of histone methylation. 12, 14 Although the functions of histone methylation and the responding histone modifiers in different physiological and pathological processes have been gradually revealed, 15, 16 the histone methylation markers and corresponding epigenetic modifiers involved in inflammatory responses need to be further investigated.
Several reports have shown that the kinds and levels of histone methylation at cytokine gene promoters mediated by KMTs or KDMs play vital roles in cytokine gene transcription and expression. For example, histone demethylase Kdm6a can promote Il6 transcription by decreasing H3K27me2/3 modification at the Il6 promoter; and Kdm6b can enhance Tnfα transcription via a similar mechanism. 17, 18 In addition, histone methyltransferase Setdb2 increases H3K9me3 modification at Cxcl1 promoter and inhibits Cxcl1 transcription. 19 Similar to H3K4me3 and H3K36me3, H3K79me2/3 modifications are often associated with gene transcriptional activation. H3K79 methylation is essential for the regulation of embryonic development, cellular differentiation and somatic reprogramming. 20, 21 However, whether H3K79me2/3 modifications are enriched at the gene promoters of inflammatory cytokine and type I IFN genes and whether they have roles in cytokine gene transcription remain unknown.
Disruptor of telomeric silencing-1-like (Dot1l) is the only confirmed H3K79 methyltransferase that can exclusively catalyze mono-, di-, and tri-methylation of H3K79. 20 Dot1l regulates proliferation and differentiation of hematological tumor cells by mediating H3K79 methylation modification at target gene promoters and then promoting the development and progress of hematological malignancies, such as MLL-rearranged leukemia. 22 Dot1l also promotes the oncogenesis of neuroblastoma by facilitating H3K79 methylation and increasing the expression of ODC1 and E2F2. 23 As a highly conservative protein in different species, Dot1l is widely expressed in various kinds of innate immune cells of mice and humans. 24, 25 However, the roles of Dot1l and Dot1l-mediated H3K79 methylation in the innate immunity and inflammatory response remain unclear.
Herein, we found that Dot1l is required for the production of IL-6 and IFN-β but not of TNF-α induced by TLRs or RNA virus infection in macrophages. Dot1l-mediated H3K79me2/3 modifications at the Il6 and Ifnb1 promoters selectively enhance Il6 and Ifnb1 transcription. Our research identifies Dot1l as an important positive epigenetic regulator in innate immunity and inflammatory responses.
MATERIALS AND METHODS
Mice C57BL/6 male mice 6-8 weeks of age were from Joint Ventures Sipper BK Experimental Animals (Shanghai, China) and bred in pathogen-free conditions. All animal experiments were conducted according to the National Institute of Health Guide for the Care and Use of Laboratory Animals, with approval from the Scientific Investigation Board of Second Military Medical University, Shanghai.
Reagents and antibodies Lipopolysaccharide (LPS) (E. coli serotype 0111:B4) was from Sigma. Poly (I:C) (528906) was from Merck. ChIP grade protein G magnetic beads (#9006), cell lysis buffer (#9803) and anti-ERK (#9102), anti-p-ERK (Thr202-Tyr204) (#9106), anti-JNK (#9258), antip-JNK (Thr183-Tyr185) (#4668), anti-p38 (#9212), anti-p-p38 (Thr180-Tyr182) (#9211), anti-IKKβ (#8943), anti-p-IKKα/β (Ser176/ 180) (#2697), anti-p65 (#8242), anti-p-p65 (Ser536) (#3033), anti-TBK1 (#3013), anti-p-TBK1(Ser172) (#5483), anti-IRF3 (#4302), and anti-p-IRF3 (Ser396) (#4947) antibodies were from Cell Signaling Technology. The anti-H3K79me2 (AY-2519) antibody was from Abway. Anti-H3K79me3 (ab2621) and anti-histone H3 (ab1791) antibodies were from Abcam. The anti-Dot1l (sc-376036) antibody was from Santa Cruz Biotechnology. The antibody against RNA polymerase II was from Active Motif (39097). The Dot1l inhibitor EPZ5676 (S7062) was from Selleckchem.
Cells and pathogens HEK293T and THP1 cell lines were from the American Type Culture Collection. Peritoneal macrophages were separated by abdomen irrigation with Dulbecco's Modified Eagle Medium (DMEM; Gibco) from mice 4 days after thioglycollate injection as described. 26 Cells were plated into cell culture materials and cultured for at least 12 h before use. HEK293T cells and peritoneal macrophages were cultured in DMEM supplemented with 10% fetal calf serum (FCS) (Gibco). THP1 cells were cultured in RPMI 1640 (Gibco) and supplemented with 10% FCS. VSV (Indiana Strain) was propagated and amplified by infection of HEK293T cells for 48 h, followed by supernatant collection and centrifugation. Sendai virus (kindly gifted by Dr. Bin Sun, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, China) was propagated in 8-10day-old embryonated chicken eggs. Viral titer was determined by TCID50 in HEK293T cells. Peritoneal macrophages or THP1 cells were treated with LPS, Poly (I:C), VSV, or SeV for the indicated time. Cytokine production levels in cell supernatants were analyzed using IFN-β (PBL Biomedical Laboratories), IL-6 and TNF-α (R&D Systems) ELISA kits according to manufacturers' instructions.
RNA interference
Peritoneal macrophages were transfected with siRNA (30 nM final concentration) using Lipofectamine RNAimax (Thermo Fisher Scientific).
The mouse-specific Dot1l-siRNA (sequence 5′-CCGAACGCAAGTCTAAGAA-3′) and control siRNA (sequence 5′-TTCTCCGAACGTGTCACGT-3′) were designed and synthesized by GenePharma (Shanghai, China).
Lentiviral transduction THP1 cells (2.5 × 10 5 /well) were cultured in six-well plates with Polybrene (Genechem, Shanghai, China) and then infected with Dot1l-siRNA (sequence 5′-CGGATCTCAAGCTCGCTAT-3′) lentivirus or control siRNA (sequence 5′-TTCTCCGAACGTGTCACGT-3′) lentivirus (25 MOI) (Genechem, Shanghai, China). After 12 h, the culture medium was changed into fresh RPMI 1640 medium containing 10% FCS. Four days after infection, THP1 cells expressing the GFP label were treated with PMA for 12 h and then treated with LPS, Poly(I:C), or VSV.
RNA quantification
Total RNA was extracted with RNA fast2000 kit (Fastagen, Shanghai, China) and reversed-transcribed with a reverse transcription kit (Takara, FSQ-101). The cDNAs of different samples were used to detect the change in expression of different genes by the LightCycler System (Roche) using the SYBR Green PCR Master Mix (Takara, QPK-201) according to the manufacturer's instructions. Data were analyzed using 2 -△△Ct method to calculate relative expression changes. The expression level of β-actin in each sample was used as an internal control. The primers for mouse β-actin, Il6, Ifnb1, and Tnfα detection were the same as those previously reported. 11 Mouse Dot1l primers were 5′-TGGAGAACTATGTCCTGATCGAC-3′ (sense) and 5′-GTGCCGCAGAAGTCCATTG-3′ (antisense). The specific primers for human genes were as follows: Dot1l, 5′-TGGAGAACTATGTCCTGATC GAC-3′ (sense) and 5′-CCTTCCACAGCTGGTGGATGCTGTC-3′ (anti sense); β-actin, 5′-GGCGGCACCACCATGTACCC T-3′ (sense) and 5′-AGGGGCCGGACTCGTCATACT-3′ (antisense); IL6, 5′-AACCTGAACC TTCCAAAGATGG-3′ (sense) and 5′-TCTGGCTTGTTCCTCACTACT -3′ (antisense); IFNB1, 5′-ATGACCAACAAGTGTCTCCTCC-3′ (sense) and 5′-G CTCATGGAAAGAGCTGTAGTG-3′ (antisense).
Immunoblot analysis
Total proteins were harvested with cell lysis buffer (Cell Signaling Technology) containing protease inhibitor "cocktail" (Calbiochem) and phenylmethylsulfonyl fluoride, followed by centrifugation (12,000 rpm, 15 min). Protein concentrations were measured with the bicinchoninic acid protein assay reagent kit (Pierce). Immunoblotting was performed with indicated antibodies as described. 26 ChIP assay ChIP assay was performed following the protocol of the ChIP assay kit (Millipore). Target gene promoter sequences in both input DNA and recovered DNA immunocomplexes were detected by Q-PCR. Data were normalized to the corresponding DNA input control. The primers used for mouse gene promoter detection were as follows: Il6 promoter (− 273 to − 93), 5′-TCCCATCAAGACATGCTCAAGTG-3′ (sense) and 5′-TGGGGCTGATTGGAAACCTTA-3′ (antisense); Tnfα promoter (− 211 to + 81), 5′-GAGATTCCTTGATGCCTGGGTGTC-3′ (sense) and 5′-GGGAGCTATTTCCAAGATGTTCTGGAG-3′ (antisense); Tnfα promoter (− 480 to − 173), 5′-CCTTATGCACCCAGCTTTCAGA AGC-3′ (sense) and 5′-GTTTGGAAAGTTGGGGACACCCAGG-3′ (antisense); Tnfα promoter (− 750 to − 445), 5′-GAGGCTCCGTG GAAAACTCACTTGG-3′ (sense) and 5′-TGCTTCTGAAAGCTGG GTGCATAAG-3′ (antisense); Ifnb1 promoter (− 126 to + 24), 5′-TCTGAGGCAGAAAGGACCAT-3′ (sense) and 5′-GTGGAGGATCCA CCTGTTGT-3′ (antisense); Il1b promoter (− 213 to + 52), 5′-ATG TGTCACTATCTGCCACCCCTTG-3′ (sense) and 5′-GGAGAGGATCCCAG ATGAGCCTATTAG-3′ (antisense); Il12b promoter (− 238 to + 55), 5′-TTCCACACCCCGAAGTCATTTCCT C-3′ (sense) and 5′-TTGCTT TGCTGCGAGCTGCCTGGTC-3′ (antisense). The primers used for human gene promoter detection were as follows: IL6 promoter (− 163 to − 4), 5′-CTGTTTAGACAATCGGTGAAGAATGG-3′ (sense) and 5′-CAATCGGTTTCTTTGCTTTGCTAAG-3′ (antisense); IFNB1 promoter (− 177 to − 12), 5′-CATTAGAAAACCTCACAGTTTGTAAATC-3′ (sense) and 5′-GAGATGGTCCTCTCTCTATTCAGAGG-3′ (antisense).
Statistical analysis
Statistical comparisons between two groups were conducted by two-tailed Student's t test. Comparisons of more than two groups were performed using one-way analysis of variance. A P value of < 0.05 was considered as statistically significant.
RESULTS
H3K79me2/3 modifications at the Il6 and Ifnb1 promoters are increased by innate stimuli To explore whether H3K79 methylation is involved in innate immune responses, we detected H3K79me2/3 modifications at the Il6, Tnfα, and Ifnb1 promoters in mouse peritoneal macrophages. H3K79me2 modifications at the Il6, Ifnb1, and Tnfα promoters were significantly increased in macrophages stimulated with Toll-like receptor (TLR) ligand LPS or Poly(I:C) or infected with VSV or SeV (Fig. 1a, b and Supplementary Figure 1a ). In addition, treatment with LPS, Poly(I:C), VSV, or SeV markedly increased H3K79me3 modification at the Il6 and Ifnb1 promoters but not at the Tnfα promoter ( Fig. 1c-d and Supplementary Figure 1b , c). Similar changes in H3K79me2/3 modifications at the Il6, Tnfα, and Ifnb1 promoters upon treatment with innate stimuli were also observed when the histone H3 antibody was used for normalization in ChIP assays, and the amount of histone H3 at the promoters of these cytokine genes showed no change (Supplementary Figures 2a-c) . However, H3K79me2 and H3K79me3 modifications at the Il1b and Il12b promoter were not upregulated in macrophages upon LPS stimulation or VSV infection (Supplementary Figures 3a, b) . These data indicate that innate immune activation preferentially upregulates H3K79me2/3 modifications at the Il6 and Ifnb1 promoters in macrophages, suggesting that H3K79me2/3 modifications are involved in innate immunity.
Dot1l expression is upregulated in macrophages by innate stimuli
As Dot1l is the confirmed H3K79 methyltransferase, 20 We further investigated whether Dot1l was involved in innate immune responses. We first found that Dot1l expression was increased in mouse peritoneal macrophages by treatment with LPS, Poly(I:C), or VSV ( Fig. 2a ). Dot1l expression was also upregulated in human THP1 cells stimulated with LPS or infected with VSV ( Fig. 2b) .
Dot1l silencing or inhibitor treatment suppresses IL-6 and IFN-β production triggered by TLR ligands and virus infection
To further explore the role of Dot1l in inflammatory responses, we first silenced Dot1l expression in mouse peritoneal macrophages with target-specific siRNA (Fig. 3a) and found that Dot1l silencing significantly inhibited the production of IL-6 and IFN-β but not of TNF-α at the mRNA and protein levels in macrophages treated with LPS, Poly(I:C), VSV, or SeV (Fig. 3b, c and Supplementary  Figures S4a, b ). Furthermore, Dot1l silencing markedly suppressed IL-6 and IFN-β production in THP1 cells stimulated with LPS or infected with VSV or SeV (Fig. 3d, e ).
We further investigated the effect of the Dot1l inhibitor EPZ5676 on cytokine production in macrophages upon treatment with innate stimuli. Dot1l inhibition by EPZ5676 decreased the production of IL-6 and IFN-β at the mRNA and protein levels in macrophages treated with LPS, Poly(I:C), or VSV (Fig. 4a, b) . Furthermore, the Dot1l inhibitor impaired the recruitment of RNA polymerase II to the Il6 and Ifnb1 promoters in macrophages upon treatment with LPS, Poly(I:C), or VSV infection (Fig. 4c ). These data indicate that Dot1l preferentially promotes IL-6 and IFN-β production triggered by TLRs or virus in macrophages, which depends on the methyltransferase activity of Dot1l.
Next, we investigated the signaling mechanism by which Dot1l enhanced the production of IL-6 and IFN-β upon TLR ligand stimulation or virus infection. We found that Dot1l silencing barely affected protein phosphorylation of MAPK and NF-κB signaling pathways in peritoneal macrophages stimulated with LPS ( Supplementary Figure 5a) . The phosphorylation levels of IRF3 and TBK1 induced by LPS or VSV were also similar between Dot1lsilenced and control macrophages ( Supplementary Figures 5a and  b) . Thus, these data demonstrate that Dot1l does not regulate the activation of MAPK or NF-κB signaling pathways initiated by TLRs or virus infection.
Dot1l preferentially binds to the Il6 and Ifnb1 promoters in response to innate stimuli As Dot1l was found to preferentially promote IL-6 and IFN-β production, we then determined whether Dot1l was recruited to the promoters of these cytokine genes in response to innate stimuli. The association of Dot1l with the proximal promoter of Il6 but not of Tnfα was significantly increased in macrophages treated with LPS, Poly(I:C), or VSV (Fig. 5a, b and Supplementary Figure 6a ). The recruitment of Dot1l to the proximal promoter of Ifnb1 was also upregulated in macrophages treated with LPS, Poly(I:C), VSV, or SeV ( Fig. 5c and Supplementary Figure 6b ). Thus, Dot1l preferentially binds to the promoters of Il6 and Ifnb1 genes during innate immune responses. Dot1l mediates H3K79me2/3 modifications at the Il6 and Ifnb1 promoters As H3K79me2/3 modifications at the Il6 and Ifnb1 promoters were increased, and H3K79 methyltransferase Dot1l was recruited to these promoters, we further investigated whether Dot1l affected H3K79me2/3 modification levels of the Il6 and Ifnb1 promoters. Dot1l silencing significantly decreased the H3K79me2 modification levels of the Il6 and Ifnb1 promoters in peritoneal macrophages treated with LPS, Poly(I:C), or VSV (Fig. 6a, b ). Dot1l silencing also downregulated the H3K79me2 modification levels of the Il6 and Ifnb1 promoters in THP1 cells treated with LPS or VSV (Fig. 6c, d) . In addition, the H3K79me3 modification levels of the Il6 and Ifnb1 promoters were downregulated in Dot1l-silenced peritoneal macrophages treated with LPS, Poly(I:C), or VSV (Fig. 6e,  f) . A decrease in H3K79me3 modification levels at the Il6 and Ifnb1 promoters was also detected in Dot1l-silenced THP1 cells treated with LPS or VSV (Fig. 6g, h) . Altogether, our data demonstrate that Dot1l selectively binds to the Il6 and Ifnb1 promoters and mediates H3K79me2/3 modifications, leading to upregulation of Il6 and Ifnb1 gene transcription and enhanced innate immune responses.
DISCUSSION
Exploring the roles of important epigenetic modification markers and their respective epigenetic modifiers in inflammation can provide a deeper insight into the development mechanism of inflammatory and autoimmune diseases. The function of H3K79 methylation-mediated transcriptional regulation in innate immunity remains poorly understood. Classic Dot1l functions cover the regulation of embryonic development, cell differentiation, senescence, and tumorigenesis; all these are dependent on its H3K79 methyltransferase activity. 20, 21 In this study, we demonstrate that H3k79me2/3 modifications at the Il6 and Ifnb1 promoters are enriched in macrophages activated by innate stimuli. Dot1l selectively binds to the Il6 and Ifnb1 promoters and facilitates H3k79me2/3 modifications, which are required for the transcriptional activation of the Il6 and Ifnb1 genes. Our results indicate that Dot1l-mediated H3k79me2/3 alteration can epigenetically enhance inflammatory responses.
Genome-wide analysis indicates a tight connection between H3K79 methylation and gene transcriptional activity. In Saccharomyces cerevisiae and flies, Dot1l and H3K79me2/3 are both found at the promoters of transcriptionally active genes. 27, 28 H3K79me2/3 modifications also exist in many promoters of transcriptionally active genes in mammalian cells. 29 In addition, H3K79me2/3 peaks are located around the transcriptional start site (TSS), which is in the vicinity of H3K4me3 peak site. 27, 30 In our study, H3K79me2/3 modifications appear around TSS regions of the Il6 and Ifnb1 promoters as well. Since the TSS regions of the Il6 or Ifnb1 promoters are essential for the binding of associated transcription factors, such as p65 or IRF3, H3K79me2/3 modifications may enhance activities of these transcription factors at the Il6 and Ifnb1 genes. In addition, we found that H3K79me2 but not H3K79me3 modification was upregulated at the Tnfα promoter in macrophages treated with innate stimuli, whereas Dot1l did not associate with the Tnfα promoter, and Dot1l silencing had no effect on Tnfα transcription. These data suggest that H3K79me3 modification is not required for Tnfα transcription, and another H3K79 methyltransferase may be responsible for H3K79me2 modification at Tnfα promoter, which needs to be further studied.
Our results indicate that Dot1l is directly recruited to the Il6 and Ifnb1 promoters but not the Tnfα promoter. As no report has shown that Dot1l contains a specific DNA-binding domain, Dot1l may specifically target-specific promoters via other binding proteins. A previous study showed that c-Myc directly interacts with Dot1l and mediates its binding to gene promoters of several epithelial-mesenchymal transition regulators in breast cancer cells. 31 However, c-Myc has not been shown to associate with the Il6 and Ifnb1 promoters and regulate the transcript of these two genes. Thus, other proteins or noncoding RNAs may be involved in the selective recruitment of Dot1l to the Il6 and Ifnb1 promoters, which needs to be further explored.
The aberrant histone modifications are tightly associated with the pathogenesis of multiple inflammatory and autoimmune diseases. 32 The overproduction of IL-6 is related to rheumatoid arthritis and multiple sclerosis, 33, 34 and the abnormal level of type I IFN is associated with systemic lupus erythematosus and insulindependent diabetes mellitus. 35, 36 Thus, the disorder of histone methylation modifications at the promoters of inflammatory cytokine and type I IFN genes leads to aberrant transcription and production of these cytokines, which contributes to the development and progress of inflammatory and autoimmune diseases. 37 However, whether H3K79me2/3 modifications are involved in inflammatory diseases and autoimmune disorders by regulating the level of inflammatory cytokines and type I IFN remains unclear. Some reports have shown that Dot1l expression significantly increases in synovial macrophages from RA patients (GSE10500) or CD16 + monocytes from SLE patients (GSE51997). 38, 39 Together with our data that Dot1l promotes innate IL-6 and IFN-β production in macrophages by mediating H3K79me2/3 modifications, these observations may indicate that Dot1l and Dot1l-mediated H3K79me2/3 modifications play roles in the pathogenesis of autoimmune diseases by affecting the expression of cytokines or other associated genes.
In conclusion, our study demonstrates that Dot1l preferentially promotes IL-6 and IFN-β production via an increase in H3K79me2/3 modifications, providing a novel epigenetic regulation pattern for inflammatory cytokines and type I IFN during innate immunity and inflammation responses. Our study also sheds new light on the treatment of inflammatory and autoimmune diseases by targeting specific aberrant histone methylation modification and the respective modifiers. 
